A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Marizomib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Biomarker; Proof of concept; Therapeutic Use
  • Sponsors Triphase Accelerator Corporation
  • Most Recent Events

    • 14 Jun 2017 Part 3 (Phase 2)has been added to treatment, includes a combination MRZ using intra-patient dose escalation, and BEV at a fixed dose.hence patient number is also increased.
    • 09 Jun 2017 Planned number of patients changed from 66 to 106.
    • 09 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top